Clinical acceptability of trimetazidine 80mg once daily compared to trimetazidine 35mg twice daily in patients with chronic stable angina pectoris: a multicentre randomised double blind study

Trial Profile

Clinical acceptability of trimetazidine 80mg once daily compared to trimetazidine 35mg twice daily in patients with chronic stable angina pectoris: a multicentre randomised double blind study

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2013

At a glance

  • Drugs Trimetazidine (Primary)
  • Indications Angina pectoris
  • Focus Adverse reactions
  • Sponsors Servier
  • Most Recent Events

    • 31 Dec 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 13 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top